AR093403A1 - COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa - Google Patents
COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFaInfo
- Publication number
- AR093403A1 AR093403A1 ARP130104094A ARP130104094A AR093403A1 AR 093403 A1 AR093403 A1 AR 093403A1 AR P130104094 A ARP130104094 A AR P130104094A AR P130104094 A ARP130104094 A AR P130104094A AR 093403 A1 AR093403 A1 AR 093403A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- heteroatoms selected
- carbon atoms
- membered
- Prior art date
Links
- 102000013264 Interleukin-23 Human genes 0.000 title abstract 2
- 108010065637 Interleukin-23 Proteins 0.000 title abstract 2
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical class OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 15
- 125000005842 heteroatom Chemical group 0.000 abstract 14
- 229910052717 sulfur Inorganic materials 0.000 abstract 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 150000002431 hydrogen Chemical class 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 101150105130 RORB gene Proteins 0.000 abstract 3
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- -1 cyclic acetal Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 230000011234 negative regulation of signal transduction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Dermatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723854P | 2012-11-08 | 2012-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093403A1 true AR093403A1 (es) | 2015-06-03 |
Family
ID=49667568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104094A AR093403A1 (es) | 2012-11-08 | 2013-11-07 | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9315494B2 (enExample) |
| EP (1) | EP2922841B8 (enExample) |
| JP (1) | JP6259463B2 (enExample) |
| KR (1) | KR102233252B1 (enExample) |
| CN (1) | CN104781252B (enExample) |
| AR (1) | AR093403A1 (enExample) |
| AU (1) | AU2013341185B2 (enExample) |
| BR (1) | BR112015010244A8 (enExample) |
| CA (1) | CA2890929A1 (enExample) |
| EA (1) | EA028526B1 (enExample) |
| IL (1) | IL238554A0 (enExample) |
| MX (1) | MX2015005272A (enExample) |
| SG (1) | SG11201503396UA (enExample) |
| TW (1) | TWI620737B (enExample) |
| WO (1) | WO2014074660A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35126A (es) | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | Ojo es alfa |
| MX2015005561A (es) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa). |
| PE20150953A1 (es) * | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| CN105992768B (zh) | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| WO2016022626A1 (en) * | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP3313840B1 (en) | 2015-06-24 | 2019-07-24 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| KR102641263B1 (ko) | 2015-06-24 | 2024-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | 헤테로아릴 치환된 아미노피리딘 화합물 |
| CN108026099B (zh) | 2015-06-24 | 2020-07-10 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| KR102097878B1 (ko) * | 2015-11-26 | 2020-04-06 | 노파르티스 아게 | 디아미노 피리딘 유도체 |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| MA48602A (fr) * | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
| US10336752B2 (en) | 2017-03-08 | 2019-07-02 | Nimbus Lakshmi, Inc. | TYK2 inhibitors, uses, and methods for production thereof |
| TW201900640A (zh) | 2017-05-11 | 2019-01-01 | 美商必治妥美雅史谷比公司 | 作為irak4抑制劑之噻吩并吡啶及苯并噻吩 |
| TWI776810B (zh) * | 2017-05-12 | 2022-09-11 | 瑞士商諾華公司 | 新穎二胺基吡啶衍生物 |
| MY205416A (en) | 2017-07-28 | 2024-10-21 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| JP7258903B2 (ja) * | 2017-11-21 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160875A1 (en) | 2018-02-13 | 2019-08-22 | Rutgers, The State University Of New Jersey | Antibacterial agents: soluble salts and aqueous formulations of pyronins |
| CN112118837B (zh) | 2018-02-13 | 2024-07-09 | 罗格斯新泽西州立大学 | 抗菌剂：o-烷基氘化派洛宁 |
| WO2019173507A1 (en) | 2018-03-06 | 2019-09-12 | Rutgers, The State University Of New Jersey | Antibacterial agents : arylalkylcarboxamido phloroglucinols |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| US12240840B2 (en) * | 2018-10-30 | 2025-03-04 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020154474A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020156311A1 (zh) * | 2019-01-28 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| KR20220035447A (ko) | 2019-07-18 | 2022-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물 |
| JP7573596B2 (ja) | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| EP4027995A4 (en) | 2019-09-13 | 2023-08-23 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND THEIR APPLICATIONS |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| JP7682191B2 (ja) | 2020-02-03 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環ヘテロアリール化合物 |
| CN112203515B (zh) * | 2020-03-11 | 2022-08-02 | 西北农林科技大学 | N-苄基苯甲酰胺类化合物作为除草剂的用途 |
| EP4136073A1 (en) * | 2020-04-14 | 2023-02-22 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| KR20230004771A (ko) | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| JP7537002B2 (ja) * | 2020-08-07 | 2024-08-20 | 南京薬石科技股▲フン▼有限公司 | Ｃｄｋ９阻害剤およびその使用 |
| CN114181257B (zh) * | 2020-09-14 | 2025-02-14 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物，包含其的药物组合物，其制备方法及其用途 |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN117098757A (zh) | 2021-02-02 | 2023-11-21 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022222470A1 (en) * | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| US20240189309A1 (en) * | 2021-02-19 | 2024-06-13 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022223497A1 (en) * | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| EP4319756A4 (en) | 2021-04-09 | 2025-02-26 | Nimbus Clio, Inc. | CBL-B MODULATORS AND USES THEREOF |
| CN119013277A (zh) | 2021-10-25 | 2024-11-22 | 凯麦拉医疗公司 | Tyk2降解剂和其用途 |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| TW202339749A (zh) * | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Ｔｙｋ２抑制劑及其組合物和方法 |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119585250A (zh) * | 2022-04-19 | 2025-03-07 | 蓝图药品公司 | Kit抑制剂 |
| EP4532485A1 (en) * | 2022-05-27 | 2025-04-09 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| KR20250057800A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도 |
| WO2024249855A1 (en) * | 2023-06-02 | 2024-12-05 | Idrx, Inc. | Combination therapy comprising kit inhibitors for use in the treatment of cancer |
| TW202529769A (zh) | 2023-09-21 | 2025-08-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JPWO2010058846A1 (ja) * | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| JP2014500254A (ja) | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
-
2013
- 2013-11-07 BR BR112015010244A patent/BR112015010244A8/pt not_active Application Discontinuation
- 2013-11-07 EA EA201590913A patent/EA028526B1/ru not_active IP Right Cessation
- 2013-11-07 KR KR1020157014693A patent/KR102233252B1/ko active Active
- 2013-11-07 SG SG11201503396UA patent/SG11201503396UA/en unknown
- 2013-11-07 US US14/441,193 patent/US9315494B2/en active Active
- 2013-11-07 AU AU2013341185A patent/AU2013341185B2/en not_active Ceased
- 2013-11-07 CA CA2890929A patent/CA2890929A1/en not_active Abandoned
- 2013-11-07 EP EP13795911.0A patent/EP2922841B8/en active Active
- 2013-11-07 WO PCT/US2013/068842 patent/WO2014074660A1/en not_active Ceased
- 2013-11-07 CN CN201380058022.7A patent/CN104781252B/zh active Active
- 2013-11-07 JP JP2015541882A patent/JP6259463B2/ja active Active
- 2013-11-07 MX MX2015005272A patent/MX2015005272A/es unknown
- 2013-11-07 TW TW102140570A patent/TWI620737B/zh not_active IP Right Cessation
- 2013-11-07 AR ARP130104094A patent/AR093403A1/es unknown
-
2015
- 2015-04-30 IL IL238554A patent/IL238554A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL238554A0 (en) | 2015-06-30 |
| JP2016506368A (ja) | 2016-03-03 |
| CN104781252A (zh) | 2015-07-15 |
| SG11201503396UA (en) | 2015-05-28 |
| MX2015005272A (es) | 2015-07-14 |
| CN104781252B (zh) | 2017-11-17 |
| KR102233252B1 (ko) | 2021-03-26 |
| WO2014074660A1 (en) | 2014-05-15 |
| KR20150081338A (ko) | 2015-07-13 |
| BR112015010244A8 (pt) | 2019-10-01 |
| EP2922841A1 (en) | 2015-09-30 |
| CA2890929A1 (en) | 2014-05-15 |
| AU2013341185A1 (en) | 2015-07-02 |
| EP2922841B1 (en) | 2017-06-07 |
| TW201422587A (zh) | 2014-06-16 |
| JP6259463B2 (ja) | 2018-01-10 |
| EA201590913A1 (ru) | 2015-10-30 |
| BR112015010244A2 (pt) | 2017-07-11 |
| EP2922841B8 (en) | 2017-08-02 |
| US9315494B2 (en) | 2016-04-19 |
| AU2013341185B2 (en) | 2017-07-13 |
| TWI620737B (zh) | 2018-04-11 |
| EA028526B1 (ru) | 2017-11-30 |
| US20150307483A1 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| CY1126106T1 (el) | Υποκατεστημενοι 2-αζαδικυκλοι και χρηση αυτων ως ρυθμιστες υποδοχεα ορεξινης | |
| AR095208A1 (es) | Pirrolotriazinas como inhibidores del canal del ión potasio | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR113895A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
| AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
| AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
| AR089889A1 (es) | Compuestos fungicidas de pirimidina | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
| AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
| AR092749A1 (es) | Compuestos farmaceuticos | |
| EA201791816A1 (ru) | Ингибиторы kv1.3 и их применение в медицине | |
| AR100327A1 (es) | Inhibidores de quinasa relacionados con tropomiosina | |
| AR098101A1 (es) | Composiciones plaguicidas y métodos relacionados | |
| AR097795A1 (es) | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| AR089887A1 (es) | Compuestos fungicidas de pirimidina | |
| AR110152A1 (es) | SULFONAS TRICÍCLICAS COMO MODULADORES DE RORg | |
| AR112695A1 (es) | Inhibidores de cdpk1, composiciones y métodos relacionados con los mismos | |
| AR089878A1 (es) | Compuestos fungicidas de pirimidina i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |